Sinogen Pharmaceutical Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Series B
- Investors
-
7
Sinogen Pharmaceutical General Information
Description
Developer and manufacturer of bacterial carrier-based biological anti-tumor drugs for the treatment of malignant tumors. The company focuses on the field of metastatic tumors and rare diseases, committing to the development of innovative anti-cancer drugs to meet the needs of domestic and international pharmaceutical markets.
Contact Information
Website
www.huajinpharmtech.comCorporate Office
- Room 101, 1st Floor, Building C5
- Science and Technology Enterprise Accelerator, Huangpu District
- Guangzhou, Guangdong
- China
Corporate Office
- Room 101, 1st Floor, Building C5
- Science and Technology Enterprise Accelerator, Huangpu District
- Guangzhou, Guangdong
- China
Sinogen Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 29-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 23-May-2022 | Completed | Startup | |||
| 4. Early Stage VC (Series A) | 25-Sep-2020 | Completed | Startup | |||
| 3. Early Stage VC | 01-Mar-2020 | Completed | Startup | |||
| 2. Seed Round | 01-Aug-2017 | $1.5M | Completed | Startup | ||
| 1. Seed Round | 25-Jul-2016 | $1.5M | $1.5M | Completed | Startup |
Sinogen Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sinogen Pharmaceutical Patents
Sinogen Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020455277-A1 | Application of methioninase gene therapy in treatment of malignant tumor | Inactive | 24-Jun-2020 | ||
| EP-4170035-A1 | Application of methioninase gene therapy in treatment of malignant tumor | Inactive | 24-Jun-2020 | ||
| EP-4170035-A4 | Application of methioninase gene therapy in treatment of malignant tumor | Inactive | 24-Jun-2020 | ||
| US-20230250451-A1 | Application of methioninase gene therapy in treatment of malignant tumor | Pending | 24-Jun-2020 | ||
| WO-2021258492-A1 | Application of methioninase gene therapy in treatment of malignant tumor | Inactive | 24-Jun-2020 | C12N9/88 |
Sinogen Pharmaceutical Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hebei Coastal Industry Investment Fund | Government | Minority | ||
| Cherami Investment Group | Asset Manager | Minority | ||
| Huarui Zhifu | Venture Capital | Minority | ||
| Yixing JIE investment management | Growth/Expansion | Minority | ||
| CICC Capital | PE/Buyout | Minority |
Sinogen Pharmaceutical FAQs
-
When was Sinogen Pharmaceutical founded?
Sinogen Pharmaceutical was founded in 2016.
-
Where is Sinogen Pharmaceutical headquartered?
Sinogen Pharmaceutical is headquartered in Guangzhou, China.
-
What industry is Sinogen Pharmaceutical in?
Sinogen Pharmaceutical’s primary industry is Drug Discovery.
-
Is Sinogen Pharmaceutical a private or public company?
Sinogen Pharmaceutical is a Private company.
-
What is Sinogen Pharmaceutical’s current revenue?
The current revenue for Sinogen Pharmaceutical is .
-
How much funding has Sinogen Pharmaceutical raised over time?
Sinogen Pharmaceutical has raised $10.7M.
-
Who are Sinogen Pharmaceutical’s investors?
Hebei Coastal Industry Investment Fund, Cherami Investment Group, Huarui Zhifu, Yixing JIE investment management, and CICC Capital are 5 of 7 investors who have invested in Sinogen Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
